RxDoctor Payments Data

Kristi Stoutjesdyk, NP

Family · Grand Rapids, MINPI 1104264613

Payments from drug & device makers

$8,934in general payments, 2019–2025

Across 172 payments — averaging $51.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$5K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$508
  • Amgen$471
  • Impel Pharmaceuticals Inc.$149
  • Biohaven Pharmaceutical Holding Company Ltd.$145
  • plus $444 from 5 others

What the payments were for

  • Speaking & faculty fees$4,50050%
  • Food & beverage$4,39349%
  • Education$420%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,934 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$9,666
Medicare patients
64
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe216$172,464
Nurtec OdtRimegepant Sulfate98$134,651
UbrelvyUbrogepant108$133,072
Emgality PenGalcanezumab-Gnlm163$122,968
Ajovy AutoinjectorFremanezumab-Vfrm64$59,105
QuliptaAtogepant41$55,094
Sumatriptan Succinate65$5,230
Candesartan Cilexetil41$4,947
Propranolol Hcl ErPropranolol Hcl40$2,204
Gabapentin63$1,723
Topiramate94$1,705
Zonisamide65$1,524
Venlafaxine Hcl ErVenlafaxine Hcl26$1,512
Duloxetine Hcl25$1,290
Pregabalin42$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,329$188,166149 claims
PfizerNurtec Odt$70$134,65198 claims
Lilly USA, LLCOlanzapine$4,888$11112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →